CellSeed

CellSeed EBIT per Employee

The EBIT per Employee of CellSeed (7776.T) as of Nov 1, 2026 is -34.87 M JPY. In the previous year, EBIT per Employee was -28.21 M JPY — a change of 23.60% (lower).

EBIT per Employee

-34.87 MJPY

YoY

23.60%

Last updated:

EBIT per Employee of CellSeed is 2025 -34.87 M JPY. EBIT per Employee of CellSeed was 2024 -28.21 M JPY. It decreases by 23.60% lower compared to the previous year.

The CellSeed EBIT per Employee history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT per Employee
Date
EBIT per Employee
Jan 1, 2018
4.67 M JPY
Jan 1, 2019
-27.53 M JPY
Jan 1, 2020
-25.65 M JPY
Jan 1, 2021
-30.20 M JPY
Jan 1, 2022
-24.86 M JPY
Jan 1, 2023
-23.26 M JPY
Jan 1, 2024
-28.21 M JPY
Jan 1, 2025
-34.87 M JPY
The CellSeed EBIT per Employee history
YEAREBIT per EmployeeYoY
-34.87 MJPY+23.60%
-28.21 MJPY+21.30%
-23.26 MJPY-6.45%
-24.86 MJPY-17.69%
-30.20 MJPY+17.76%
-25.65 MJPY-6.84%
-27.53 MJPY-689.72%
4.67 MJPY-114.60%
-31.98 MJPY-2.54%
-32.82 MJPY+73.33%
-18.93 MJPY-5.65%
-20.07 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

CellSeed Stock analysis

What does CellSeed do? CellSeed Inc. generates revenue through two primary business segments. The Regenerative Medical Support segment sells temperature-responsive cell incubators developed by the company. These incubators are used in medical research and treatment applications. The Cell Sheet Regeneration Medical segment focuses on developing cell sheet regenerative medical products for therapeutic use. Both segments contribute to the company's revenue streams through product sales and research activities. The company serves medical institutions and research organizations requiring advanced regenerative medicine solutions. The Regenerative Medical Support segment's products are specifically designed for temperature-responsive cell culture applications. These incubators support cell growth and maintenance in controlled environments. The Cell Sheet Regeneration Medical segment's products involve innovative cell sheet technologies for tissue regeneration. These products are targeted at medical professionals and research facilities seeking advanced regenerative treatments. The company's focus on regenerative medicine positions it within the healthcare technology sector. CellSeed Inc. develops and sells its own proprietary products without external branding. The temperature-responsive cell incubators and cell sheet regenerative medical products are the company's core offerings. The company's business model relies on direct sales of these products to medical and research institutions. The products are sold under the company's own brand name without third-party branding. CellSeed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CellSeed stock

EBIT per Employee of CellSeed is -34.87 M JPY in 2025.

EBIT per Employee of CellSeed changed from -28.21 M JPY to -34.87 M JPY, representing a 23.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT per Employee CellSeed since 2006 – with annual values, charts, and detailed analysis.

EBIT per employee measures operating profit per employee, showing how efficiently the workforce generates operating earnings.

EBIT per Employee's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBIT per Employee's CellSeed historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Workforce — CellSeed

All Key Metrics — CellSeed